- Home
- FTI vs HOLX Comparison
FTI vs HOLX Comparison
Compare FTI & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FTI | HOLX |
|---|---|---|
| Founded | 1884 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medical Electronics |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6B | 16.6B |
| IPO Year | N/A | 1990 |
Fundamental Metrics
Financial Performance| Metric | FTI | HOLX |
|---|---|---|
| Price | $60.02 | $75.20 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 13 |
| Target Price | $50.11 | ★ $77.89 |
| AVG Volume (30 Days) | ★ 3.5M | 2.7M |
| Earning Date | 02-19-2026 | 01-29-2026 |
| Dividend Yield | ★ 0.33% | N/A |
| EPS Growth | ★ 59.09 | N/A |
| EPS | 2.28 | ★ 2.40 |
| Revenue | ★ $9,803,000,000.00 | $4,126,500,000.00 |
| Revenue This Year | $10.41 | $6.01 |
| Revenue Next Year | $7.04 | $5.29 |
| P/E Ratio | ★ $26.39 | $31.27 |
| Revenue Growth | ★ 11.44 | 2.17 |
| 52 Week Low | $22.12 | $51.90 |
| 52 Week High | $60.49 | $75.36 |
Technical Indicators
Market Signals| Indicator | FTI | HOLX |
|---|---|---|
| Relative Strength Index (RSI) | 82.45 | 61.83 |
| Support Level | $54.32 | $74.50 |
| Resistance Level | $57.64 | $74.99 |
| Average True Range (ATR) | 1.72 | 0.43 |
| MACD | 0.23 | -0.01 |
| Stochastic Oscillator | 92.90 | 95.62 |
Price Performance
Historical ComparisonAbout FTI TechnipFMC plc
TechnipFMC is the largest provider of offshore oilfield services, offering integrated deep-water offshore oil and gas development solutions that span the full spectrum of subsea equipment and subsea construction services. The company also provides various pieces of surface equipment used with onshore oil and gas wells. TechnipFMC originated with the 2017 merger of Technip and FMC Technologies.
About HOLX Hologic Inc.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.